Daniel Wicklein Selected Research

Fos-Related Antigen-2

6/2022	Fra-2 overexpression upregulates pro-metastatic cell-adhesion molecules, promotes pulmonary metastasis, and reduces survival in a spontaneous xenograft model of human breast cancer.
6/2010	The transcription factor Fra-2 promotes mammary tumour progression by changing the adhesive properties of breast cancer cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Daniel Wicklein Research Topics

Disease

20	Neoplasms (Cancer) 06/2022 - 10/2005
17	Neoplasm Metastasis (Metastasis) 06/2022 - 06/2010
5	Breast Neoplasms (Breast Cancer) 06/2022 - 06/2010
4	Adenocarcinoma 06/2021 - 05/2013
4	Leukemia 01/2020 - 01/2012
4	Melanoma (Melanoma, Malignant) 01/2018 - 01/2012
3	Pancreatic Neoplasms (Pancreatic Cancer) 09/2014 - 01/2014
2	Circulating Neoplastic Cells 01/2022 - 01/2020
2	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 05/2011
2	Colonic Neoplasms (Colon Cancer) 01/2022 - 08/2012
2	Prostatic Neoplasms (Prostate Cancer) 01/2020 - 04/2014
2	Inflammation (Inflammations) 04/2014 - 06/2011
2	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2014 - 05/2011
1	Chronic Obstructive Pulmonary Disease (COPD) 01/2022
1	Carcinoma (Carcinomatosis) 06/2021
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 10/2019
1	Triple Negative Breast Neoplasms 01/2019
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 06/2014
1	Neuroblastoma 04/2014
1	Peritoneal Neoplasms 05/2013
1	Myeloid Sarcoma (Chloroma) 01/2013
1	Hypereosinophilic Syndrome (Loeffler Endocarditis) 01/2013
1	Disease Progression 01/2012
1	Pdgfra-Associated Chronic Eosinophilic Leukemia 01/2012
1	Vasculitis (Vasculitides) 06/2006
1	Granulomatosis with Polyangiitis (Wegener's Granulomatosis) 06/2006
1	Crohn Disease (Crohn's Disease) 06/2006
1	Granuloma 06/2006
1	Peanut Hypersensitivity (Peanut Allergy) 10/2004
1	Hypersensitivity (Allergy) 05/2004

Drug/Important Bio-Agent (IBA)

10	SelectinsIBA 06/2022 - 08/2012
8	LigandsIBA 06/2022 - 10/2005
7	P-SelectinIBA 06/2022 - 05/2011
5	Cell Adhesion MoleculesIBA 06/2022 - 01/2012
4	Small Interfering RNA (siRNA)IBA 01/2022 - 01/2012
4	E-SelectinIBA 01/2022 - 05/2011
3	Neural Cell Adhesion Molecule L1 (L1 Cell Adhesion Molecule)IBA 01/2018 - 07/2014
2	Fos-Related Antigen-2IBA 06/2022 - 06/2010
2	Pharmaceutical PreparationsIBA 01/2022 - 01/2020
2	Messenger RNA (mRNA)IBA 01/2022 - 01/2020
2	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2014
2	Biological ProductsIBA 01/2020 - 01/2014
2	Transcription Factors (Transcription Factor)IBA 10/2019 - 05/2011
2	CEACAM1 ProteinIBA 01/2018 - 01/2012
2	Activated-Leukocyte Cell Adhesion Molecule (Neurolin)IBA 06/2014 - 01/2013
2	CarbohydratesIBA 04/2014 - 05/2004
2	Hyaluronic Acid (Hyaluronan)IBA 04/2014 - 05/2012
2	AllergensIBA 10/2004 - 05/2004
1	RNA (Ribonucleic Acid)IBA 01/2022
1	CytokinesIBA 01/2022
1	Bortezomib (Velcade)FDA Link 01/2022
1	Proteasome InhibitorsIBA 01/2022
1	CA-19-9 Antigen (CA 19-9 Antigen)IBA 01/2022
1	Integrin alphaVIBA 06/2021
1	Polysaccharides (Glycans)IBA 01/2020
1	PronaseIBA 01/2020
1	EpitopesIBA 01/2020
1	Sialyl Lewis X AntigenIBA 01/2020
1	Neuraminidase (Sialidase)IBA 01/2020
1	Microfilament Proteins (Actin Binding Proteins)IBA 10/2019
1	Laminin (Merosin)IBA 01/2019
1	MicroRNAs (MicroRNA)IBA 01/2019
1	Jagged-1 ProteinIBA 01/2018
1	Epithelial Cell Adhesion MoleculeIBA 09/2014
1	Immunoglobulins (Immunoglobulin)IBA 04/2014
1	silk elastin-like protein (SELP)IBA 04/2014
1	Cadherins (E-Cadherin)IBA 04/2014
1	IntegrinsIBA 04/2014
1	GlycosyltransferasesIBA 04/2014
1	LectinsIBA 04/2014
1	Carcinoembryonic AntigenIBA 01/2014
1	Monoclonal AntibodiesIBA 01/2014
1	A-Form DNA (A-DNA)IBA 01/2014
1	Biomarkers (Surrogate Marker)IBA 01/2014
1	Phenobarbital (Luminal)FDA Link 05/2013
1	Blocking AntibodiesIBA 01/2013
1	nilotinib FDA Link 01/2012
1	Tyrosine Kinase InhibitorsIBA 01/2012
1	Imatinib Mesylate (Gleevec)FDA Link 01/2012
1	beta-tricalcium phosphateIBA 06/2011
1	Brachyury protein (Brachyury)IBA 05/2011
1	Myeloblastin (Proteinase 3)IBA 06/2006
1	AutoantigensIBA 06/2006
1	AutoantibodiesIBA 06/2006
1	Peptides (Polypeptides)IBA 10/2005
1	Immunotoxins (Immunotoxin)IBA 10/2005
1	Immunoglobulin FragmentsIBA 10/2005
1	Immunoglobulin E (IgE)IBA 05/2004
1	Glycoproteins (Glycoprotein)IBA 05/2004

Therapy/Procedure

6	Therapeutics 01/2018 - 10/2005
1	Subcutaneous Injections 06/2022
1	Injections 01/2014
1	Remission Induction 01/2012
1	Transplantation 06/2010